Clinical Trial Update: SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study) [Phase 4]

View source ↗

Summary

A Phase 4 SACRA clinical trial evaluating the combination of an SGLT-2 inhibitor with an ARB in patients with type 2 diabetes mellitus and nocturnal hypertensio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nocturnal Hypertension
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Jichi Medical University | Conditions: Nocturnal Hypertension, T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Status: COMPLETED